<DOC>
	<DOC>NCT00447941</DOC>
	<brief_summary>Study assessing pharmacokinetics, pharmacodynamics, safety, and tolerability of oral doses of SCA-136 in healthy male Japanese subjects</brief_summary>
	<brief_title>Safety, PK and PD Study in Healthy Male Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Inclusion Criteria Men aged 20 to 45 years at the time of obtaining informed consent. Body mass index (BMI) in the range of 18.5 to 25.0 kg/m2 and body weight â‰¥ 50 kg. Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12lead electrocardiogram (ECG). Exclusion Criteria Presence or history of any disorder that may prevent the successful completion of the study. Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion (ADME) of the test article (eg, resection of liver, kidney, or gastrointestinal tract).</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>